Technical Analysis for TILS - Tiziana Life Sciences Pl

Grade Last Price % Change Price Change
D 58.5 8.33% 4.50
TILS closed up 8.33 percent on Wednesday, October 20, 2021, on 73 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical TILS trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Wide Range Bar Range Expansion 0.00%
Stochastic Reached Overbought Strength 0.00%
Multiple of Ten Bullish Other 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Older End-of-Day Signals for TILS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Tiziana Life Sciences Pl Description

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib is in Phase II clinical trials for thymic carcinoma. The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. The Company is involved in the development of Bcl-3 inhibitors. The Company's lead clinical candidate, CB1, is a Bcl-3 inhibitor with potent anti-metastatic activity.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Science Clinic Disease Life Sciences Cancer Diseases Drugs Oncology Clinical Trial Immunology Antibody Cancers Enzymes Kinase Stage Biotechnology

Is TILS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 195.0
52 Week Low 30.0
Average Volume 407,419
200-Day Moving Average 87.09
50-Day Moving Average 57.78
20-Day Moving Average 52.90
10-Day Moving Average 54.06
Average True Range 4.74
ADX 15.72
+DI 16.20
-DI 21.66
Chandelier Exit (Long, 3 ATRs) 44.79
Chandelier Exit (Short, 3 ATRs) 59.21
Upper Bollinger Bands 57.33
Lower Bollinger Band 48.46
Percent B (%b) 1.13
BandWidth 16.76
MACD Line -0.82
MACD Signal Line -1.82
MACD Histogram 1.0001
Fundamentals Value
Market Cap 113.85 Million
Num Shares 195 Million
EPS -4.60
Price-to-Earnings (P/E) Ratio -12.72
Price-to-Sales 0.00
Price-to-Book 36.23
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 79.50
Resistance 3 (R3) 77.33 68.17 76.00
Resistance 2 (R2) 68.17 62.82 69.25 74.83
Resistance 1 (R1) 63.33 59.51 65.75 65.50 73.67
Pivot Point 54.17 54.17 55.38 55.25 54.17
Support 1 (S1) 49.33 48.82 51.75 51.50 43.33
Support 2 (S2) 40.17 45.51 41.25 42.17
Support 3 (S3) 35.33 40.17 41.00
Support 4 (S4) 37.50